217 related articles for article (PubMed ID: 11380598)
1. N-acetyl-L-cysteine exerts direct anti-aggregating effect on human platelets.
Anfossi G; Russo I; Massucco P; Mattiello L; Cavalot F; Trovati M
Eur J Clin Invest; 2001 May; 31(5):452-61. PubMed ID: 11380598
[TBL] [Abstract][Full Text] [Related]
2. L-arginine modulates aggregation and intracellular cyclic 3,5-guanosine monophosphate levels in human platelets: direct effect and interplay with antioxidative thiol agent.
Anfossi G; Russo I; Massucco P; Mattiello L; Perna P; Tassone F; Trovati M
Thromb Res; 1999 Jun; 94(5):307-16. PubMed ID: 10379819
[TBL] [Abstract][Full Text] [Related]
3. Adenosine increases human platelet levels of cGMP through nitric oxide: possible role in its antiaggregating effect.
Anfossi G; Russo I; Massucco P; Mattiello L; Cavalot F; Balbo A; Trovati M
Thromb Res; 2002 Jan; 105(1):71-8. PubMed ID: 11864710
[TBL] [Abstract][Full Text] [Related]
4. Insulin increases guanosine-3',5'-cyclic monophosphate in human platelets. A mechanism involved in the insulin anti-aggregating effect.
Trovati M; Massucco P; Mattiello L; Mularoni E; Cavalot F; Anfossi G
Diabetes; 1994 Aug; 43(8):1015-9. PubMed ID: 7518780
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of rat platelet aggregation by the diazeniumdiolate nitric oxide donor MAHMA NONOate.
Homer KL; Wanstall JC
Br J Pharmacol; 2002 Dec; 137(7):1071-81. PubMed ID: 12429580
[TBL] [Abstract][Full Text] [Related]
6. Platelet resistance to the antiaggregating effect of N-acetyl-L-cysteine in obese, insulin-resistant subjects.
Anfossi G; Russo I; Massucco P; Mattiello L; Trovati M
Thromb Res; 2003 Apr; 110(1):39-46. PubMed ID: 12877907
[TBL] [Abstract][Full Text] [Related]
7. Insulin exerts opposite effects on platelet function at physiological and supraphysiological concentrations.
Anfossi G; Massucco P; Mattiello L; Piretto V; Mularoni E; Cavalot F; Paoletti G; Trovati M
Thromb Res; 1996 Apr; 82(1):57-68. PubMed ID: 8731510
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein E inhibits platelet aggregation through the L-arginine:nitric oxide pathway. Implications for vascular disease.
Riddell DR; Graham A; Owen JS
J Biol Chem; 1997 Jan; 272(1):89-95. PubMed ID: 8995232
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the L-arginine:nitric oxide pathway in human platelets.
Radomski MW; Palmer RM; Moncada S
Br J Pharmacol; 1990 Oct; 101(2):325-8. PubMed ID: 1701676
[TBL] [Abstract][Full Text] [Related]
10. Tonic inhibitory action by nitric oxide on spontaneous mechanical activity in rat proximal colon: involvement of cyclic GMP and apamin-sensitive K+ channels.
Mulè F; D'Angelo S; Serio R
Br J Pharmacol; 1999 May; 127(2):514-20. PubMed ID: 10385253
[TBL] [Abstract][Full Text] [Related]
11. Evidence for a cyclic GMP-independent mechanism in the anti-platelet action of S-nitrosoglutathione.
Gordge MP; Hothersall JS; Noronha-Dutra AA
Br J Pharmacol; 1998 May; 124(1):141-8. PubMed ID: 9630353
[TBL] [Abstract][Full Text] [Related]
12. Nitric oxide-dependent and independent effects on human platelets treated with peroxynitrite.
Brown AS; Moro MA; Masse JM; Cramer EM; Radomski M; Darley-Usmar V
Cardiovasc Res; 1998 Nov; 40(2):380-8. PubMed ID: 9893732
[TBL] [Abstract][Full Text] [Related]
13. Effects of nebivolol on human platelet aggregation.
Falciani M; Rinaldi B; D'Agostino B; Mazzeo F; Rossi S; Nobili B; Rossi F; Filippelli A
J Cardiovasc Pharmacol; 2001 Dec; 38(6):922-9. PubMed ID: 11707696
[TBL] [Abstract][Full Text] [Related]
14. cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase.
Moro MA; Russel RJ; Cellek S; Lizasoain I; Su Y; Darley-Usmar VM; Radomski MW; Moncada S
Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1480-5. PubMed ID: 8643658
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of platelet aggregation by S-nitroso-cysteine via cGMP-independent mechanisms: evidence of inhibition of thromboxane A2 synthesis in human blood platelets.
Tsikas D; Ikic M; Tewes KS; Raida M; Frölich JC
FEBS Lett; 1999 Jan; 442(2-3):162-6. PubMed ID: 9928994
[TBL] [Abstract][Full Text] [Related]
16. The insulin-induced increase of guanosine-3',5'-cyclic monophosphate in human platelets is mediated by nitric oxide.
Trovati M; Massucco P; Mattiello L; Piretto V; Cavalot F; Mularoni E; Anfossi G
Diabetes; 1996 Jun; 45(6):768-70. PubMed ID: 8635651
[TBL] [Abstract][Full Text] [Related]
17. Studies on inhibition of human platelet function by sodium nitroprusside. Kinetic evaluation of the effect on aggregation and cyclic nucleotide content.
Anfossi G; Russo I; Massucco P; Mattiello L; Balbo A; Cavalot F; Trovati M
Thromb Res; 2001 May; 102(4):319-30. PubMed ID: 11369425
[TBL] [Abstract][Full Text] [Related]
18. Suppressed anti-aggregating and cGMP-elevating effects of sodium nitroprusside in platelets from patients with stable angina pectoris.
Chirkov YY; Chirkova LP; Horowitz JD
Naunyn Schmiedebergs Arch Pharmacol; 1996 Oct; 354(4):520-5. PubMed ID: 8897457
[TBL] [Abstract][Full Text] [Related]
19. Enhanced nitric oxide and cyclic GMP formation plays a role in the anti-platelet activity of simvastatin.
Chou TC; Lin YF; Wu WC; Chu KM
Br J Pharmacol; 2008 Mar; 153(6):1281-7. PubMed ID: 18264124
[TBL] [Abstract][Full Text] [Related]
20. The role of cGMP hydrolysing phosphodiesterases 1 and 5 in cerebral artery dilatation.
Kruuse C; Rybalkin SD; Khurana TS; Jansen-Olesen I; Olesen J; Edvinsson L
Eur J Pharmacol; 2001 May; 420(1):55-65. PubMed ID: 11412839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
